Back to the top

Break Through Cancer and Revolution Medicines Collaborate to Study Biomarkers for RAS(ON) Inhibitor in Pancreatic Cancer

Break Through Cancer and Revolution Medicines Collaborate to Study Biomarkers for RAS(ON) Inhibitor in Pancreatic Cancer News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org Collaboration with Revolution Medicines to Study Biomarkers for RAS(ON) Multi-Selective Inhibitor in Pancreatic Cancer The expanded phase 1 clinical trial is using serial biopsies and blood samples to analyze the tumor response to RMC-6236 at an unprecedented level of detail.   (CAMBRIDGE, MASS.) December 19, 2024 – Break Through Cancer has launched a collaborative cohort for a Phase 1 study of RMC-6236, a compound developed by Revolution Medicines that is designed to suppress multiple......

Continue reading

Break Through Cancer Launches Team to Prevent Lung Cancer Recurrence with the Hope of Long-term Cures.

Break Through Cancer Launches Team to Prevent Lung Cancer Recurrence with the Hope of Long-term Cures. News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org Break Through Cancer Launches Team to Prevent Lung Cancer Recurrence with the Hope of Long-term Cures. Top cancer researchers unite in radical collaboration to target residual lung cancer cells remaining after initial therapy. (CAMBRIDGE, MASS.) December 05, 2024 – Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer frequently strikes younger people who have never smoked, including those aged......

Continue reading

Break Through Cancer Announces First Patient Enrolled in Phase 2 Trial Targeting Residual Disease in AML

News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org   Break Through Cancer Announces First Patient Enrolled in Phase 2 Trial  Targeting Residual Disease in AML The novel study explores the effects of menin inhibition in acute myeloid leukemia with minimal residual disease as an endpoint. (CAMBRIDGE, MASS.) November 1, 2024 – Break Through Cancer, a Boston-based cancer research foundation, has launched a clinical trial to explore if an investigational drug can eliminate minimal residual disease (MRD) in acute myeloid leukemia (AML). AML often responds well to initial treatment, but residual cancer cells frequently cause relapse. Break Through Cancer’s......

Continue reading

No More “Wait and See”: Two Clinical Trials Target the Origins of Recurrent Ovarian Cancer

News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org   No More “Wait and See”: Two Clinical Trials Target the Origins of Recurrent Ovarian Cancer Break Through Cancer scientists are evaluating a “second-look” technique to measure and destroy persistent cancer cells resistant to frontline chemotherapy. (CAMBRIDGE, MASS.) September 26, 2024 – After initial therapy to treat ovarian cancer, a small number of cancer cells, undetectable on scans, often linger in the body. These cells, referred to as minimal residual disease (MRD), are the seed from which cancer can and does recur for most women diagnosed with stage III or......

Continue reading

Break Through Cancer and ALK Positive, Inc. Team Up to Conquer ALK-Positive Lung Cancer with a $2 Million, Multi-year, Research Partnership

News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org   Break Through Cancer and ALK Positive, Inc. Team Up to Conquer ALK-Positive Lung Cancer with a $2 Million, Multi-year, Research Partnership   CAMBRIDGE, MA, May 9, 2024 /Break Through Cancer announces a new partnership with ALK Positive Inc. (ALK Positive), a foundation funded by patients with ALK-positive lung cancer and their families. ALK Positive and Break Through Cancer are joining forces to fund a new initiative in lung cancer research with the hope of creating durable responses and cures for patients with ALK-positive lung cancer. ALK Positive is the......

Continue reading

Reimagining Cancer Team Science: Six Hallmarks of Cancer Collaboration

News Release For Immediate Release Media Contact: Kari McHugh KM@breakthroughcancer.org   Reimagining Cancer Team Science: Six Hallmarks of Cancer Collaboration A new commentary in Cancer Discovery presents a playbook of best practices for cancer team science in the modern era. (CAMBRIDGE, MASS.) April 4, 2024 – The oncology community has a powerful opportunity to speed the creation of impactful new treatments by adopting a modern playbook for collaboration, according to scientists from Break Through Cancer and other team-oriented cancer organizations working together in a commentary in the journal Cancer Discovery Jesse Boehm and Tyler Jacks of Break Through Cancer, a......

Continue reading

Break Through Cancer Summit Advances ‘Radical Collaboration’ Among Top Cancer Centers

Scientists and funders unite to tackle urgent projects across four deadly cancers at annual meeting. Carol Aghajanian, M.D., and other members of the Targeting Minimal Residual Disease in Ovarian Cancer TeamLab at the 2023 Break Through Cancer Summit (KIAWAH, SOUTH CAROLINA) November 5, 2023 -- Today, Break Through Cancer, a collaborative medical research foundation, welcomes over 120 scientists and physicians from five leading cancer centers, as well as representatives from ARPA-H, to its annual Summit, November 5th to 8th in Kiawah, South Carolina. The gathering arrives at an unprecedented moment for oncology, when breakthroughs in genomic technologies, machine learning, and novel......

Continue reading

Break Through Cancer Launches Two TeamLabs Targeting Acute Myelogenous Leukemia (AML)

Break Through Cancer Launches Two TeamLabs Targeting Acute Myelogenous Leukemia (AML) Novel research program embracing radical collaboration to discover potential AML treatments (CAMBRIDGE, MASS.) MAY 16, 2023 – Break Through Cancer, a collaborative medical research organization empowering researchers and physicians from top cancer research institutions to intercept and find cures for several of the world’s deadliest cancers, is announcing the launch of the Targeting Clonal Hematopoiesis to Prevent AML TeamLab and the Eradicating Minimal Residual Disease in AML TeamLab. AML begins in the blood-forming cells of the bone marrow and rapidly moves into the bloodstream, where it can quickly spread......

Continue reading

Break Through Cancer, A New Research Consortium, Names First Class of Scientists Designated as Catalysts for Innovation and Collaboration

Break Through Cancer, A New Research Consortium, Names First Class of Scientists Designated as Catalysts for Innovation and Collaboration Highly skilled professional scientists at partner institutes will spur development of novel approaches to understanding cancer and developing new treatment strategies (CAMBRIDGE, MASS.) APRIL 25, 2023 – Break Through Cancer, a foundation designed to find new solutions to some of the most intractable challenges in cancer, has named four individuals as Break Through Cancer Scientists—Neelkanth Bardhan, Sreyashi Basu, Paola A. Guerrero, and Thomas R. Pisanic II. They are professional scientists who cooperate on and lead projects with the skills, knowledge, and......

Continue reading

MD Anderson receives over $10 million from Break Through Cancer to support collaborative research with leading cancer centers

MD Anderson receives over $10 million from Break Through Cancer to support collaborative research with leading cancer centers Funding is part of $50 million in grants to teams at five cancer centers charged to work together  Contact: Clayton Boldt, Ph.D. Office: 713-792-9518 Cell: 409-673-5582 crboldt@mdanderson.org  HOUSTON ― The University of Texas MD Anderson Cancer Center...

Continue reading